GLSI Greenwich LifeSciences, Inc.
Nasdaq · SEC CIK 1799788 · EDGAR
- Bought, last 12 months
- $586.3K 11 purchases by 1 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 118 since 2021-12-16, latest 2026-07-30 06:05
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Patel Snehal | CEO, CFO, Dir, 10% | $586.3K | — |
Transactions 106
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-07-30 06:05 | 2026-07-28+ | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $13.43 | +2,200 | 5.61M | +0.0% | +$29.6K |
| 2026-07-29 06:05 | 2026-07-27 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $13.62 | +1,500 | 5.61M | +0.0% | +$20.4K | |
| M | 2026-07-27 06:15 | 2026-07-23+ | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $13.06 | +3,600 | 5.61M | +0.1% | +$47.0K |
| 2026-01-15 | 2026-01-13 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $29.83 | +1,800 | 5.60M | +0.0% | +$53.7K | |
| 2026-01-14 | 2026-01-12 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $27.54 | +2,900 | 5.60M | +0.1% | +$79.9K | |
| 2026-01-05 | 2025-12-31 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $21.36 | +4,300 | 5.60M | +0.1% | +$91.8K | |
| 2026-01-02 | 2025-12-30 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $21.73 | +2,900 | 5.60M | +0.1% | +$63.0K | |
| 2025-12-19 | 2025-12-18 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $12.62 | +4,100 | 5.59M | +0.1% | +$51.7K | |
| 2025-11-28 | 2025-11-25 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $8.37 | +4,600 | 5.59M | +0.1% | +$38.5K | |
| 2025-11-12 | 2025-11-07 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $8.43 | +10.6K | 5.58M | +0.2% | +$89.4K | |
| 2025-11-04 | 2025-10-31 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.26 | +2,300 | 5.57M | +0.0% | +$21.3K | |
| 2025-04-29 | 2025-04-25 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.88 | +3,600 | 5.57M | +0.1% | +$35.6K | |
| 2025-04-22 | 2025-04-17 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $8.98 | +5,400 | 5.57M | +0.1% | +$48.5K | |
| 2025-04-08 | 2025-04-07 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.10 | +3,600 | 5.56M | +0.1% | +$32.8K | |
| 2025-04-07 | 2025-04-04 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $8.73 | +5,500 | 5.56M | +0.1% | +$48.0K | |
| 2025-01-13 | 2025-01-10 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $12.51 | +2,500 | 5.55M | +0.0% | +$31.3K | |
| M | 2025-01-08 | 2025-01-06+ | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $13.58 | +2,900 | 5.55M | +0.1% | +$39.4K |
| 2025-01-07 | 2025-01-03 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $12.95 | +3,400 | 5.55M | +0.1% | +$44.0K | |
| 2025-01-06 | 2025-01-02 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $11.97 | +2,000 | 5.54M | +0.0% | +$23.9K | |
| 2025-01-03 | 2024-12-31 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $11.36 | +2,400 | 5.54M | +0.0% | +$27.3K | |
| 2025-01-02 | 2024-12-30 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $11.12 | +3,200 | 5.54M | +0.1% | +$35.6K | |
| 2024-11-25 | 2024-11-21 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $12.91 | +1,000 | 264.1K | +0.4% | +$12.9K | |
| 2024-09-30 | 2024-09-26 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $14.63 | +1,500 | 5.54M | +0.0% | +$21.9K | |
| 2024-09-16 | 2024-08-12 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $13.85 | +800 | 263.1K | +0.3% | +$11.1K | |
| 2024-08-08 | 2024-08-06 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $13.81 | +2,000 | 5.53M | +0.0% | +$27.6K | |
| 2024-08-07 | 2024-08-05 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $13.18 | +5,500 | 5.53M | +0.1% | +$72.5K | |
| 2024-08-05 | 2024-08-02 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $15.15 | +1,000 | 262.3K | +0.4% | +$15.2K | |
| 2024-07-24 | 2024-07-23 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $15.89 | +1,500 | 5.53M | +0.0% | +$23.8K | |
| 2024-07-22 | 2024-07-18 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $16.00 | +1,000 | 261.3K | +0.4% | +$16.0K | |
| 2024-06-17 | 2024-06-13 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $14.30 | +174.8K | 5.53M | +3% | +$2.50M | |
| 2024-04-03 | 2024-04-01 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $19.08 | +3,000 | 5.35M | +0.1% | +$57.2K | |
| 2024-03-26 | 2024-03-22 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $19.98 | +2,500 | 5.35M | +0.0% | +$50.0K | |
| 2024-03-22 | 2024-03-20 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $17.68 | +1,500 | 5.35M | +0.0% | +$26.5K | |
| A | 2024-03-07 | 2024-03-05 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $12.49 | +3,500 | 5.34M | +0.1% | +$43.7K |
| 2024-03-07 | 2024-03-05 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $12.49 | +30.5K | 5.34M | +0.6% | +$380.9K | |
| 2024-03-06 | 2024-03-04 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $13.03 | +4,100 | 5.34M | +0.1% | +$53.4K | |
| 2024-02-21 | 2024-02-16 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $11.16 | +10.8K | 5.34M | +0.2% | +$120.5K | |
| 2024-02-20 | 2024-02-15 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $11.07 | +12.7K | 5.33M | +0.2% | +$140.6K | |
| 2023-11-14 | 2023-11-10 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $10.17 | +5,000 | 5.31M | +0.1% | +$50.9K | |
| 2023-11-07 | 2023-11-03 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.11 | +3,500 | 5.31M | +0.1% | +$31.9K | |
| 2023-10-31 | 2023-10-27 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $8.57 | +500 | 260.3K | +0.2% | +$4,285 | |
| 2023-10-30 | 2023-10-26 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $7.97 | +2,500 | 5.30M | +0.0% | +$19.9K | |
| 2023-10-27 | 2023-10-25 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $7.91 | +2,500 | 5.30M | +0.0% | +$19.8K | |
| 2023-10-12 | 2023-10-10 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.07 | +1,000 | 5.30M | +0.0% | +$9,070 | |
| 2023-10-05 | 2023-10-04 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $8.63 | +2,000 | 5.30M | +0.0% | +$17.3K | |
| 2023-09-28 | 2023-09-26 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $8.71 | +600 | 259.8K | +0.2% | +$5,226 | |
| 2023-09-21 | 2023-09-19 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $8.95 | +4,000 | 5.30M | +0.1% | +$35.8K | |
| 2023-09-13 | 2023-09-11 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.48 | +1,000 | 5.29M | +0.0% | +$9,480 | |
| 2023-08-24 | 2023-08-22 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.97 | +1,000 | 5.29M | +0.0% | +$9,970 | |
| 2023-08-08 | 2023-08-04 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $10.55 | +2,000 | 5.29M | +0.0% | +$21.1K | |
| 2023-07-25 | 2023-07-21 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.20 | +1,000 | 5.29M | +0.0% | +$9,200 | |
| 2023-07-17 | 2023-07-13 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $9.49 | +250 | 259.2K | +0.1% | +$2,372 | |
| 2023-05-18 | 2023-05-17 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $11.69 | +1,000 | 5.29M | +0.0% | +$11.7K | |
| 2023-05-02 | 2023-04-28 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $11.22 | +250 | 259.0K | +0.1% | +$2,805 | |
| 2023-04-21 | 2023-04-19 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $11.10 | +7,000 | 5.29M | +0.1% | +$77.7K | |
| 2023-04-20 | 2023-04-18 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $11.12 | +2,000 | 5.28M | +0.0% | +$22.2K | |
| 2023-04-12 | 2023-04-11 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $12.42 | +5,000 | 5.27M | +0.1% | +$62.1K | |
| 2023-04-12 | 2023-04-11 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $11.87 | +1,000 | 258.7K | +0.4% | +$11.9K | |
| 2023-03-16 | 2023-03-15 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $12.71 | +250 | 257.7K | +0.1% | +$3,178 | |
| 2023-03-13 | 2023-03-10 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $12.12 | +1,000 | 2.74M | +0.0% | +$12.1K | |
| 2023-02-28 | 2023-02-24 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $15.40 | +250 | 257.5K | +0.1% | +$3,850 | |
| 2023-02-22 | 2023-02-17 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $16.53 | +600 | 2.74M | +0.0% | +$9,918 | |
| 2023-02-14 | 2023-02-10 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $18.68 | +1,000 | 2.74M | +0.0% | +$18.7K | |
| 2023-02-07 | 2023-02-03 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $20.84 | +250 | 257.2K | +0.1% | +$5,210 | |
| 2023-01-31 | 2023-01-27 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $19.35 | +2,000 | 2.73M | +0.1% | +$38.7K | |
| 2023-01-30 | 2023-01-27 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $19.20 | +250 | 257.0K | +0.1% | +$4,800 | |
| 2023-01-24 | 2023-01-20 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $17.37 | +1,500 | 2.73M | +0.1% | +$26.1K | |
| 2023-01-17 | 2023-01-13 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $16.50 | +250 | 256.7K | +0.1% | +$4,125 | |
| 2023-01-10 | 2023-01-06 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $15.18 | +1,500 | 2.73M | +0.1% | +$22.8K | |
| 2023-01-03 | 2022-12-29 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $15.19 | +4,000 | 2.73M | +0.1% | +$60.8K | |
| 2022-12-20 | 2022-12-16 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $13.01 | +1,000 | 2.73M | +0.0% | +$13.0K | |
| 2022-12-20 | 2022-12-16 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $12.94 | +250 | 256.5K | +0.1% | +$3,235 | |
| 2022-12-13 | 2022-12-09 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $13.11 | +2,000 | 2.72M | +0.1% | +$26.2K | |
| 2022-12-06 | 2022-12-02 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $13.98 | +250 | 256.2K | +0.1% | +$3,495 | |
| 2022-12-06 | 2022-12-02 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $13.84 | +1,000 | 2.72M | +0.0% | +$13.8K | |
| 2022-11-04 | 2022-11-02 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $8.79 | +2,000 | 2.72M | +0.1% | +$17.6K | |
| 2022-10-17 | 2022-10-14 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.75 | +3,000 | 2.72M | +0.1% | +$29.2K | |
| 2022-10-11 | 2022-10-07 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.72 | +2,000 | 2.72M | +0.1% | +$19.4K | |
| 2022-10-04 | 2022-09-30 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.46 | +1,000 | 2.71M | +0.0% | +$9,460 | |
| 2022-10-03 | 2022-09-29 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.23 | +1,000 | 2.71M | +0.0% | +$9,230 | |
| 2022-06-27 | 2022-06-24 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.13 | +22.5K | 2.71M | +0.8% | +$205.7K | |
| I | 2022-06-27 | 2022-06-24 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $9.13 | +6,465 | 2.71M | +0.2% | +$59.0K |
| 2022-06-17 | 2022-06-16 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $7.13 | +8,000 | 2.68M | +0.3% | +$57.0K | |
| 2022-06-15 | 2022-06-14 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $7.91 | +12.0K | 2.68M | +0.5% | +$94.9K | |
| 2022-06-13 | 2022-06-10 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $8.33 | +12.0K | 2.66M | +0.5% | +$100.0K | |
| 2022-06-10 | 2022-06-09 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $10.90 | +4,500 | 1.24M | +0.4% | +$49.0K | |
| 2022-06-08 | 2022-06-07 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $8.55 | +6,000 | 1.24M | +0.5% | +$51.3K | |
| 2022-06-06 | 2022-06-03 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $8.35 | +9,250 | 1.23M | +0.8% | +$77.2K | |
| 2022-06-03 | 2022-06-02 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $7.38 | +6,774 | 1.22M | +0.6% | +$50.0K | |
| 2022-04-26 | 2022-04-25 | GLSI | Daugherty Frank Joseph | Chief Medical Off, Dir | P - Purchase | $16.25 | +1,000 | 90.1K | +1% | +$16.2K | |
| 2022-04-22 | 2022-04-21 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $16.09 | +6,000 | 1.22M | +0.5% | +$96.5K | |
| 2022-04-21 | 2022-04-19 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $16.74 | +6,000 | 1.21M | +0.5% | +$100.4K | |
| 2022-04-20 | 2022-04-19 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $16.74 | +500 | 256.0K | +0.2% | +$8,370 | |
| 2022-02-14 | 2022-02-11 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $19.80 | +5,500 | 1.20M | +0.5% | +$108.9K | |
| 2022-02-08 | 2022-02-04 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $19.59 | +5,000 | 1.20M | +0.4% | +$98.0K | |
| 2022-02-01 | 2022-01-31 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $18.47 | +500 | 255.5K | +0.2% | +$9,235 | |
| 2022-01-24 | 2022-01-21 | GLSI | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $16.33 | +500 | 255.0K | +0.2% | +$8,165 | |
| 2022-01-24 | 2022-01-21 | GLSI | Hallock Kenneth | Dir | P - Purchase | $16.32 | +300 | 397.3K | +0.1% | +$4,896 | |
| 2022-01-19 | 2022-01-18 | GLSI | Thompson Jaye | VP Clinical Reg. Affairs | P - Purchase | $18.87 | +500 | 254.5K | +0.2% | +$9,435 | |
| 2022-01-18 | 2022-01-13 | GLSI | Patel Snehal | CEO, CFO, Dir, 10% | P - Purchase | $19.99 | +1,000 | 1.19M | +0.1% | +$20.0K |
Purchase Sale Sale after option exercise All abbreviations